Time in Target Range for Blood Pressure and Adverse Health Outcomes: A Systematic Review
- PMID: 39801461
- DOI: 10.1161/HYPERTENSIONAHA.124.24013
Time in Target Range for Blood Pressure and Adverse Health Outcomes: A Systematic Review
Abstract
Background: Blood pressure (BP) time in target range (TTR) reflects the proportion of time that BP measurement is within a specified target range. We aim to summarize the evidence for relationships between TTR and adverse health outcomes.
Methods: Seven databases were searched. After quality assessment and data extraction, meta-analyses were performed to generate pooled estimates of the association (hazard ratios) between TTR and health outcomes. Primary outcomes were all-cause mortality and cardiovascular death. Secondary outcomes included major adverse cardiovascular events, myocardial infarction, stroke, heart failure, atrial fibrillation, and adverse kidney events.
Results: In all, 21 studies were included, mostly rated at low risk of bias. TTR was defined by systolic BP (SBP) in 15 studies and by both SBP and diastolic BP in 6 studies. Per SD increase of TTR was associated with significantly decreased risks of all-cause mortality (110-130 mm Hg SBP TTR: hazard ratios, 0.85 [95% CI, 0.82-0.89]; 120-140 mm Hg SBP TTR: 0.81 [95% CI, 0.70-0.94]; and 70-80 mm Hg diastolic BP TTR: 0.88 [95% CI, 0.83-0.93]), cardiovascular death (110-130 mm Hg SBP TTR: 0.83 [95% CI, 0.78-0.87]; 120-140 mm Hg SBP TTR: 0.76 [95% CI, 0.65-0.89]; and 70-80 mm Hg diastolic BP TTR: 0.85 [95% CI, 0.80-0.90]), major adverse cardiovascular events (120-140 mm Hg SBP TTR: 0.76 [95% CI, 0.70-0.83]), and heart failure (110-130 mm Hg SBP TTR: 0.84 [95% CI, 0.76-0.93] and 120-140 mm Hg SBP TTR: 0.78 [95% CI, 0.68-0.89]). However, there was not sufficient support for the association of TTR with myocardial infarction, stroke, atrial fibrillation, or adverse kidney events.
Conclusions: Higher TTR was associated with reduced risks of all-cause mortality, cardiovascular death, major adverse cardiovascular events, and heart failure, highlighting the importance of sustained BP control in clinical practice.
Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42023486437.
Keywords: blood pressure; cardiovascular diseases; death; hypertension; secondary prevention.
Conflict of interest statement
None.
Similar articles
-
Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis.Hypertension. 2024 Nov;81(11):2329-2339. doi: 10.1161/HYPERTENSIONAHA.124.23597. Epub 2024 Sep 12. Hypertension. 2024. PMID: 39263736
-
Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis.JAMA Cardiol. 2017 Jul 1;2(7):775-781. doi: 10.1001/jamacardio.2017.1421. JAMA Cardiol. 2017. PMID: 28564682 Free PMC article.
-
Blood pressure lowering efficacy of renin inhibitors for primary hypertension.Cochrane Database Syst Rev. 2017 Apr 5;4(4):CD007066. doi: 10.1002/14651858.CD007066.pub3. Cochrane Database Syst Rev. 2017. PMID: 28379619 Free PMC article.
-
Determining the Optimal Systolic Blood Pressure for Hypertensive Patients: A Network Meta-analysis.Can J Cardiol. 2018 Dec;34(12):1581-1589. doi: 10.1016/j.cjca.2018.08.013. Epub 2018 Aug 10. Can J Cardiol. 2018. PMID: 30414702
-
Association of Systolic Blood Pressure Time in Target Range With Cardiovascular Events Among PRECISION Participants.J Clin Hypertens (Greenwich). 2025 Jul;27(7):e70009. doi: 10.1111/jch.70009. J Clin Hypertens (Greenwich). 2025. PMID: 40627752 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous